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Abstract
Prostate cancer (PCa) is the second most commonly occurring cancer in men, with over a million new cases every year
worldwide. Tumor growth and disease progression is mainly dependent on the Androgen Receptor (AR), a ligand dependent
transcription factor. Standard PCa therapeutic treatments include androgen-deprivation therapy and AR signaling inhibitors.
Despite being successful in controlling the disease in the majority of men, the high frequency of disease progression to
aggressive and therapy resistant stages (termed castrate resistant prostate cancer) has led to the search for new therapeutic
targets. The p90 ribosomal S6 kinase (RSK1-4) family is a group of highly conserved Ser/Thr kinases that holds promise as a
novel target. RSKs are effector kinases that lay downstream of the Ras/Raf/MEK/ERK signaling pathway, and aberrant
activation or expression of RSKs has been reported in several malignancies, including PCa. Despite their structural
similarities, RSK isoforms have been shown to perform nonredundant functions and target a wide range of substrates
involved in regulation of transcription and translation. In this article we review the roles of the RSKs in proliferation and
motility, cell cycle control and therapy resistance in PCa, highlighting the possible interplay between RSKs and AR in
mediating disease progression. In addition, we summarize the current advances in RSK inhibitor development and discuss
their potential clinical benefits.
Background
Prostate Cancer (PCa) is a major health problem and it is a
leading cause of cancer-related death in men. In 2020, ~1.4
million new cases of PCa were diagnosed globally and
nearly 500 thousand men died from the disease [1].
Treatments for organ-confined PCa include surgery and
brachytherapy, and on average 87% of patients survive for
5 years or longer [2]. Tumor growth is usually dependent
upon androgen, the male sex hormone, and hence patients
with disease that has spread from the prostate capsule, are
often treated with antiandrogens or luteinizing hormone-
releasing hormone (LHRH) agonists. These aim to target
the androgen signaling pathway, by blocking the Androgen
Receptor (AR) or inhibiting androgen synthesis
respectively. Although initially successful in the majority
of patients, these therapies invariably fail and the tumor
progresses to the aggressive Castration-Resistant Prostate
Cancer (CRPC) stage. Few treatment options exist for
CRPC and hence there is a need to identify novel ther-
apeutic targets for this stage of the disease. A deep
understanding of the signaling mechanisms that take place
throughout disease progression is of paramount importance
for the identification of specific and novel drug targets. One
family of interest is the p90 ribosomal S6 kinases (RSKs),
which lie downstream of the Mitogen-Activated Protein
Kinase (MAPK) signaling pathway. These kinases have
been found to be overexpressed/hyperactivated in a number
of tumor types, including PCa [3]. This review summarizes
our current understanding of the role of RSKs in PCa
proliferation, cell cycle, cell motility, and therapy
resistance.
Origin of prostate cancer
The development of PCa is a multistep process induced by
genetic and epigenetic alterations, but it is still a matter of



















debate as to what the exact mechanisms of PCa initiation
are. The accumulation of these mutations facilitates the
cells to acquire an oncogenic phenotype. A background of
inherited genetic mutations can also increase the risk of
developing PCa and determine its aggressiveness [4].
Similarly, several additional factors have also been asso-
ciated with an increased risk of PCa development: (i) age,
75% of PCa patients in Europe are diagnosed over the age
of 65 [5]; (ii) ethnicity, black men with African ancestry
have a higher incidence than other ethnicities [6]; (iii)
external factors such as smoking, obesity, and drug use
have also been associated with PCa development [7].
These inherited genetic or accumulated epigenetic
alterations can cause the development of prostatic
intraepithelial neoplasia (PIN), which can progress to
adenocarcinoma [8]. The types of mutations associated
with PIN are predominantly chromosomal deletions,
which results in loss of function of tumor suppressor
genes, resulting in an increase in cellular proliferation.
Further accumulation of genetic alterations drives disease
progression. This is often induced by gene duplications or
gene fusions, resulting in gain of function and over-
activation of the existing proliferative signals [9]. As the
disease progress to more aggressive stages, the number of
genetic alterations increases. Indeed, analysis of PCa
patient samples shows that several distinct mutations are
prominent in late stage PCa, while these are rare in early
stages of the disease [10]. Importantly, a number of
alterations in PCa have been shown to directly or indir-
ectly affect AR function [11]. Early disease mutations are
often thought to cause dysregulation of proliferative
pathways, such as MAPK or Phosphoinositide 3-Kinase
(PI3K), which in turn activates the AR [12].
The androgen receptor
The AR belongs to the Steroid Receptor subfamily, along
with the glucocorticoid (GR), mineralocorticoid (MR),
oestrogen (ER) and progesterone (PR) receptors. The AR
functions as a transcription factor, which recognizes and
binds to specific DNA sequences, called Androgen
Responsive Elements (AREs), present in the regulatory
regions of target genes. The primary function of the AR is
to regulate gene expression in the male sex organs through
the entirety of life, which is also vital for the maintenance of
the prostate gland [13]. The AR has a modular domain
structure, consisting of the N-Terminal Domain (NTD), a
central DNA Binding Domain (DBD) and the C-terminal
Ligand Binding Domain (LBD) (Fig. 1). The DBD and
LBD are connected by a linker region termed the hinge,
which is important in dimerization and nuclear localization
[14]. The DBD is essential for interacting with DNA, whilst
the LBD, as the name suggests, binds ligands [15]. There
are also additional regulatory regions in the AR, termed
Activation Function 1 and 2 (AF-1, AF-2). AF-1 is located
in the flexible NTD and recruits co-regulators for tran-
scription, whilst AF-2 is located in the LBD and has been
shown to regulate AF-1 activity by recruiting co-regulators
which facilitate full transcriptional activity [16] (Fig. 1).
Multiple studies have focused on the characterization of
the AR and have shown that several steps are required for
its activation (Fig. 2). In the absence of ligand, the AR is
inactive and bound to chaperones (e.g., the heat shock
proteins Hsp70 and Hsp90) in the cytoplasm which stabilize
the AR and prevents its degradation [17, 18]. AR activation
is triggered by hormone signaling. Testosterone passively
diffuses through the cell membrane into the cytoplasm
Fig. 1 Schematic representation of the Androgen Receptor domain
structure. The AR consists of an N-terminal Domain/Activation
Function-1 (NTD/AF-1), DNA binding Domain (DBD), Hinge region
and Ligand binding domain/Activation Function-2 (LBD/AF-2).
Phosphorylation sites are highlighted with black arrows with corre-
sponding residue numbers. Horizontal lines depict AR domains
involved in (i) dimerization, (ii) transactivation and binding of co-
regulators, (iii) DNA binding, (iv) nuclear localization and (v) ligand
binding.
Fig. 2 The Androgen Receptor signalling pathway. Schematic
representation of Androgen Receptor activation. (1) Ligand diffuses
across bilayer and binds to the AR. (2) Ligand binding causes a
conformational change and dissociation of the heat shock protein (hsp)
complex. (3) Activated AR monomers homodimerize and translocate
to the nucleus. (4) AR dimer binds to Androgen Response Elements
(AREs) located in the regulatory regions of target genes. (5) Co-
regulators bind to receptor and promote target gene transcription.
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where it is converted into dihydrotestosterone (DHT) by 5-
α-reductase. DHT binds to the AR causing a conformational
change, promoting interaction between the NTD and LBD.
This stabilizes the AR, the heat shock proteins dissociate,
which promotes the formation of homodimers [14]. Cryo-
Electron Microscopy analysis of the AR has demonstrated
that surfaces of the LBD, DBD, and NTD are involved in
this dimerization [16] (Fig. 1). The AR-ligand complex
translocates into the nucleus, where it binds AREs [19]. To
initiate gene expression, the AR recruits co-regulators and
the basal transcriptional machinery [20] (Fig. 2).
The AR does not function exclusively in the male
reproductive system. In fact, the AR is also known to reg-
ulate multiple secondary sites. Early work on mouse AR
Knock Out models highlighted that the AR regulates bone
and muscle growth, metabolism homeostasis, the cardio-
vascular and the hemopoietic systems, and has a neuro-
protective role in the brain [21]. Furthermore, in vivo
imaging of AR activity (using an AR responsive luciferase
reporter system) in transgenic mice highlighted AR activity
in e.g., the salivary glands, the eye (and associated glands),
adipose tissue, spleen, and regions of the brain [22].
AR activity can be modulated via several different
posttranslational modifications: acetylation, methylation,
SUMOylation, ubiquitination and most significantly, phos-
phorylation [23]. Specifically, 18 phosphorylation sites
have been identified on the AR, with the majority located on
the AF1 (Fig. 1) [24]. Several kinases target the AR and
influence its transcriptional program [25]. Among these
kinases, the RSK family is of particular interest. This pro-
tein family has a wide and diverse range of cellular roles,
including regulation of cell division, survival, and migra-
tion. Importantly, RSKs have been linked to cancer for their
ability to mediate tumorigenesis and metastasis [26, 27]. For
example, RSK2 has been shown to directly bind [28] and
phosphorylate the Estrogen Receptor-α (ERα) at Ser167
[29], resulting in an increased proliferation of Breast Cancer
(BCa) cells [28, 30]. Despite these initial results, very few
studies have investigated the role(s) of the different RSK
isoforms in hormone-driven cancers, such as PCa.
RSK structure and activation
The RSK family of serine/threonine kinases comprises four
closely related proteins (RSK1-4), which are the most
downstream and critical effectors of the MAPK pathway
[31]. RSKs contain two distinct kinase domains in the same
polypeptide chain. This originated as a result of a gene
fusion event and not gene duplication since the N-Terminal
Kinase Domain (NTKD) belongs to the AGC kinase group,
while the C-Terminal Kinase Domain (CTKD) belongs to
the CAMKII group [32]. These catalytic domains have a
high sequence similarity in the four isoforms, whilst the N-
and C-termini are not conserved (Fig. 3). The NTKD and
CTKD are connected by a linker region of ~100 amino
acids, which contains the Turn Motif (TM) and the
Hydrophobic Motif (HM), two essential AGC kinase reg-
ulatory motifs. The C-terminus contains two further func-
tional elements: the ERK D-domain (D-d) and the
autoinhibitory domain, which prevents substrate and ATP
binding to the CTKD [26] (Fig. 3).
RSK activation is tightly regulated and 4–5 stepwise
phosphorylation events are required to reach full kinase
activity [31]. The cascade is initiated by activation of
Extracellular signal-Regulated Kinase 1/2 (ERK1/2),
docked onto the D-d, which phosphorylates the CTKD and
two residues (only one in RSK4 [33]) on the TM. The
CTKD becomes active and phosphorylates the HM. Inter-
estingly, the only known substrate of the CTKD is its own
linker region. The phosphorylated HM and TM recruit and
stabilize the interaction with PDK1 [34]. PDK1 then
phosphorylates and activates the NTKD of RSK1-3, but not
RSK4 which has autophosphorylation activity [33]. The
RSKs can then phosphorylate a wide range of substrates
[31, 35]. In an early attempt to identify substrate specificity,
Philip Cohen’s group, using a library of peptides related to
the N-terminus of glycogen synthase, showed that RSKs
preferentially phosphorylate S residues over T and target
substrates containing a consensus motif RXRXXpS or
RRXpS [36, 37]. More recently, Roux et al. suggested that
RSKs preferentially phosphorylate substrates containing the
RXRXXpS sequence, highlighting the requirement for R
residues at position −5 and −3 [38]. Analysis of consensus
sequences recognized by individual protein kinases reveals
high level of similarities among basophilic kinases, which
includes the majority of known Ser/Thr protein kinases
[39]. This is in line with earlier evidence showing that some
AGC kinases can redundantly phosphorylate overlapping
sites on substrates, further complicating the assignment of a
specific substrate to a kinase within a signaling pathway
[40, 41]. Indeed, several RSKs substrates can also be
Fig. 3 Schematic representation of the RSKs domain structure.
Percentage sequence similarity of the RSK1 and RSK2/3/4 domains:
N-terminal region (N-term), N-terminal kinase domain (NTKD); linker
region (Linker); C-terminal kinase domain (CTKD) and the C-
terminus (C-term). Motifs are highlighted in the structure with black
arrows: Activation loop(s); Hydrophobic Motif (HM); Turn Motif
(TM); ERK Docking Domain (D-domain).
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targeted by p70 ribosomal S6 kinase (S6K), Protein Kinase
B (Akt), Protein Kinase A (PKA) and serum- and
glucocorticoid-induced protein kinase (SGK) [40, 41].
While RSKs, and kinases in general, preferentially phos-
phorylate residues within the consensus motif, recent
structural and biochemical studies have shown that substrate
recognition can be driven by docking interactions with
regions distant from the phosphorylation and the kinase
catalytic sites. It has also been shown that temporally and
spatially regulated complex interactions are required for
substrate phosphorylation in vivo [42]. This is in line with
evidence suggesting that RSK-isoform specific features
[27, 43] and substrate recognition [44] may be driven by the
non-conserved N- and/or C-termini, which are far from the
kinase catalytic pocket.
An increasing number of studies have shown that RSKs
play an important role in cancer progression and chemore-
sistance [45]. However, the lack of comprehensive studies
investigating the different RSK family members has limited
our understanding of the roles of the four RSK isoforms in
oncogenesis [27]. This is particularly relevant in PCa;
despite several studies investigating the role of RSK1/2 in
the disease (discussed here below), no study has investi-
gated the roles of RSK3/4 in PCa. This is quite surprising,
since in similar hormone-sensitive cancers such as BCa,
RSK4 downregulation was shown to correlate with Estro-
gen Receptor (ERα) upregulation and cancer progression
[46, 47]. Conversely, overexpression of RSK4 was shown
to inhibit doxorubicin chemoresistance, proliferation and
migration, and to increase apoptosis in BCa cells [48].
Future studies should therefore aim to dissect the roles of all
RSK isoforms in the same cancer type.
The role of RSKs in prostate cancer
proliferation
In one of the first studies to focus on the roles of RSKs in
PCa, Clark et al. [49] showed that RSK2 regulates the
proliferation of the PCa cell lines LNCaP and PC3. Analysis
of patient samples demonstrated that RSK1/2 protein levels
were elevated 2.5–3.5-fold in PCa biopsies compared to
normal prostate tissue [49]. Furthermore, overexpression
and/or hyperactivation of RSK2 was linked with an increase
in Prostate Specific Antigen (PSA) expression in the
androgen-sensitive human prostate adenocarcinoma cell
line LNCaP [49]. Elevated PSA levels correlates with PCa
progression and the expression of this protein has been used
as a biomarker in diagnosis and treatment decision making
for decades [50]. Expression of PSA is regulated by the AR
[51] and RSK2 indirectly upregulates the expression of this
protease via regulation of the AR transcriptional program
[49]. Earlier studies from the same group showed that RSK2
phosphorylates ERα on S167 enhancing its transcriptional
activity [29]. Based on this, Clark et al. [49] investigated if
RSK2 regulates AR in a similar manner. Using kinase
phosphorylation assays they showed that RSK2 does not
phosphorylate the two more likely phosphorylation sites of
the AR, S208 and S778, indicating that the mechanisms of
regulation of AR and ERα is different. Specifically, com-
pared to the control, RSK2 only caused a twofold increase
in phosphorylation of the AR, versus a 150-fold increase in
phosphorylation of ERα [49]. Instead, it appears that RSK2
enhancement of AR activity is via regulation of the tran-
scriptional co-regulator p300/cAMP Response Element-
Binding protein (CREB) Binding Protein (CBP). In fact,
earlier studies showed that RSKs recognize and bind the
CH3 domain of p300 and antagonistically regulate tran-
scription of CREB [52]. In a similar mechanism, but con-
verse manner, RSK2 binding to p300 was shown to
agonistically regulate the AR transcriptional program,
increasing PSA expression fivefold (Fig. 4A). This was
further validated using E1A, a viral oncoprotein which is
known to bind p300/CBP and compete with RSK2 for the
binding to p300/CBP [53].
Co-transfection of LNCaP cells with E1A, RSK2 and
p300, reduced RSK2-induced transcriptional activity two-
to threefold [49]. While the authors excluded direct AR
phosphorylation, kinase activity experiments were carried
out using short AR and ERα peptides and not the full-length
proteins, which are challenging to purify [54]. Furthermore,
the design of the AR peptides, used to investigate these
phosphorylation events, was based only on the RSKs
recognition motif RXRXXS/T. This has several limitations
since RSKs have been shown to preferentially, but not
exclusively, phosphorylate this motif. For example, Akt
Substrate of 160 kDa (AS160) (T568), Activating Tran-
scription Factor 4 (ATF4) (S245, S251), C-Fos (S362),
Eukaryotic translation Initiation Factor 2a (eIF2A) (S52),
Y-Box Binding protein 1 (YB1) (S102), p65 (S536) are
phosphorylated by RSKs but lack the RXRXXS/T recog-
nition sequence [26]. Furthermore, recent studies have
shown that ERα directly binds RSK2 and that it is the
shuttling of the ERα-RSK2 complex to the nucleus, and not
the phosphorylation of S167 on ERα, that activates a pro-
neoplastic transcriptional program [28]. It is therefore still a
matter of debate if RSKs bind to the AR as a co-regulator,
or bind and phosphorylate the AR.
Initial analysis of PCa patient samples showed that RSKs
were highly phosphorylated and localized in the nucleus of
bone metastases, which was not observed in other stages of
the disease [55]. Further analysis showed that over-
expression of constitutively activated RSK1 in the PCa cell
line C4-2B4, injected into femurs of mouse models,
enhanced tumor growth, likely by increasing PCa cell sur-
vival in the bone microenvironment. Conversely,
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knockdown of RSK1, and to a lesser extent RSK2, in PC3
cells derived from PCa bone metastasis caused a reduction
of the osteolytic lesions when injected into mouse femurs
[55]. Differently from previously published data by Clark
et al. [49] showing that inhibition of RSKs using
SL0101 significantly reduced LNCaP and PC3 cell pro-
liferation, overexpression of RSK1 in C4-2B4 and knock-
down of RSK1 in PC3 cells increased and decreased
anchorage-independent growth respectively, but not pro-
liferation. These differences may be linked to the culture
conditions used and/or to the use of SL0101, which lacks
specificity and inhibits in a non-uniform way all RSK iso-
forms [26].
Yu et al. [55] showed that RSK1 promotes cell survival
and inhibits apoptosis by causing a reduction in
phosphorylation of p38 MAPK and c-Jun N-terminal kinase
(JNK), a reduction in expression of Inhibitor-of-Growth
protein 3 (ING3) and Cytoskeleton-Associated Protein 2
(CKAP2), and an increase in expression of Protein-Tyrosine
Kinase 6 (PTK6) [55] (Fig. 4A). Indeed, previous studies
have shown that RSK2 inactivates Apoptosis Signal-
regulating Kinase 1 (ASK1) by phosphorylating it on
T1109 and T1326. This blocks ASK1 phosphorylation of
Mitogen-Activated Protein Kinase Kinase 4/7 (MKK4/
MKK7) and MKK3/MKK6, which in turn prevents acti-
vation of JNK and p38 MAPK, respectively, resulting in
inhibition of apoptosis [56]. Studies on LNCaP cells have
shown that JNK and p38 MAPK activates apoptosis by
promoting increased expression of the apoptotic protein
Bax, Cytochrome C, and concomitant increased activity of
Fig. 4 Summary of the role of
the RSK family in PCa
progression and therapy
resistance. Schematic
representation of how RSK
signalling regulates PCa (A)
proliferation, (B) cell cycle, (C)
cell motility and (D) therapy
resistance. Solid arrows depict
signalling events while dashed
arrows depict signalling events
inhibited by RSKs. Red arrows
depict a decrease in expression
while green arrows depict an
increase in expression. Brackets
are used to summarize the
overall cellular outcome.
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caspase 3 and reduced expression of the anti-apoptotic
protein B-Cell Lymphoma 2 (BCL-2) [57] (Fig. 4A). The
pro-metastatic function of RSK1 in PCa was also linked to
the activation of an RSK-dependent transcriptional pro-
gramme. Overexpression of RSK1 in C4-2B4 caused a
reduction of ING3 and CKAP2 mRNA levels (65% and
80% respectively), and a significant (~40 fold) increase in
PTK6 mRNA levels [55]. Interestingly, PTK6 is commonly
found to be overexpressed in PCa patients [50]. This is
linked to the ability of RSK1/2 to directly phosphoregulate
CREB, promoting changes in expression of its transcrip-
tional targets in metastatic cancers [55, 56] (Fig. 4A).
RSK regulation of the cell cycle
A study by Chen et al. [58] was key in improving our
understanding of the role of RSKs in cell cycle progression
in PCa. Specifically, RSK1/2 were shown to inhibit Double
Stranded Break (DSB) regulation at the G2/M checkpoint in
PC3 cells. In heathy cells, DSBs in DNA are recognized by
the Mre11-Rad50-Nbs1 (MRN) complex, which recruits the
kinase ATM, which in turn phosphorylates several targets,
such as p53, Checkpoint Kinase 1/2 (Chk1/2), Breast
Cancer type 1 susceptibility protein (BRCA1), Nbs1, γ-
H2AX [59–62] resulting in cell cycle arrest and DNA
repair, or apoptosis [63]. Failure of this pathway leads to the
accumulation of mutations or the loss of segments of
chromosomal DNA, which can result in various diseases,
including cancer [58, 64]. Chen et al. [58] showed that
RSK2 phosphorylates Mre11 on S676, causing a direct
disruption of Mre11 binding to dsDNA. This prevents
Ataxia Telangiectasia Mutated (ATM) recruitment to the
DSB site and its activation. Importantly, overactivation of
RSK2 in PC3 cells caused a reduction in phosphorylation of
ATM and a concomitant reduction in phosphorylation of
Nbs1 and γ-H2AX, two ATM substrates. This results in G2/
M progression and proliferation even in the presence of
DNA damage. This has the potential to result in disease
progression by facilitating replication of damaged DNA,
which is likely to promote accumulation of further muta-
tions [65] (Fig. 4B).
RSK1/2 have also been shown to regulate G2/M transi-
tion in PC3 cells by phosphorylating Cdc25 A and B on
residues S293/295 and S353/T355 respectively (Fig. 4B).
These phosphorylation events were shown to increase PC3
M-phase inducing activities [66]. The Cdc25 isoforms
facilitate G2/M transition via formation of Cyclin Depen-
dent Kinase (CDK) complexes. Regulation of the Cdc25
isoforms via phosphorylation has been attributed to several
kinases, many of which are Cdc25 substrates and down-
stream targets of its substrates, thus promoting a feed-
forward mechanism [67]. Since the RSKs are not substrates
of the Cdc25 isoforms, Wu et al. [66] hypothesized that the
RSKs could be responsible for initiating the G2/M feed-
forward mechanism through Cdc25 phosphorylation. It
remains to be fully elucidated if the RSKs regulation of
Cdc25 can be interlinked with the interaction of RSK2 with
Mre11. Inhibition of ATM [58] could prevent activation of
the downstream kinases Chk1 and Chk2. Chk1 in turn
would be unable to phosphorylate Cdc25A and promote its
degradation [68]. This could cause accumulation of
Cdc25A, which dephosphorylates inhibitory phosphoryla-
tion sites on CDKs (e.g., CDK1 Y14 and Y15) and in turn
prevent cell cycle arrest [68] (Fig. 4B).
The role of RSKs in cell motility
An increasing number of studies has connected RSKs to
cell motility [27] and this has been linked to an increase in
metastasis in PCa. RSK1/2 were shown to regulate a con-
served pro-motility program in both healthy and tumori-
genic prostate cells [69]. Specifically, Doehn et al. [69]
used a series of selective inhibition experiments to show
that RSKs regulate multilayering, wound healing, chemo-
taxis and cell invasiveness via the Fos-Related Antigen 1
(FRA1) transcriptional program in PCa (Fig. 4C). Inter-
estingly, RSKs were shown to regulate FRA1 in different
ways in different cell types: in MCF10A (breast) cells
RSKs stimulated FRA1 expression, while in MDCK (kid-
ney) cells RSKs phosphoactivated FRA1. This phosphor-
ylation was not mapped onto FRA1, but based on the RSKs
phosphorylation of c-Fos (a FRA1 homologue), it was
proposed that RSKs phosphorylate FRA1 at S252 [69].
Importantly, FRA1 appears to regulate the expression of
~23% of the genes induced by RSKs signaling. In addition,
the authors highlighted that this mechanism could con-
tribute to a cell motility autocrine loop across all epithelial
cells, which has previously been shown to exist in squa-
mous cell carcinomas [70].
RSK2 has been shown to regulate a conserved pro-
motility program across multiple cell types, including the
PCa cell line DU145, through inactivation of integrin β
[71]. This prevents the formation of the fibronectin matrix,
resulting in inhibition of cell adhesion and promotion of
migration. Gawecka et al. [71] elegantly showed that RSK2
interacts with the protein complex that binds to the integrin
β tails. This presents several advantages, since activation of
RSK2 allows for rapid phosphorylation of filamin A at
S2152, which promotes its binding to the integrin β tails.
The association of RSK2/filamin A with integrin β tails
disrupts the association of the integrin complex with the
actin cytoskeleton and in turn prevents the formation of
actin stress fibers [71] (Fig. 4C). A similar pro-motility
program has been reported in the induction of metastasis of
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squamous carcinoma and colon cancer cells [72]. Epidermal
Growth Factor (EGF) was shown to activate the MAPK
pathway and RSKs, causing a reduction in cell adhesions
following the same model proposed by Gawecka et al. [71].
However, in this case EGF also stimulated an additional
pathway, the Rho/Rho kinase pathway, which was shown to
partially contribute to the phosphorylation of Filamin A.
Inhibitor studies highlighted that the RSKs were the pre-
dominant Filamin A kinases, but in the squamous carci-
noma and colon cancer cells RSKs and Rho kinase co-
operatively phosphorylate Filamin A [72]. In a related study
investigating the link between RSKs and metastasis in
Glioblastoma (GBM), Shi et al. [73] showed that, down-
stream of EGF signaling, RSK2 phosphorylates Leukemia-
Associated Rho Guanine exchange factor (LARG) on
S1288, which in turn binds and activates RhoA GTPase,
resulting in increased cellular migration and invasion. It
would be interesting to investigate if this represents an
RSK2-mediated feedback pathway that controls phosphor-
ylation of Filamin A.
The role of RSKs in therapy resistance
Inactivation or evasion of the apoptotic cell death program
in PCa is often associated with Hormone Therapy (HT), a
common treatment option for the disease, which targets the
AR transcriptional program [74]. In fact, PCa is sig-
nificantly dependent on androgens and the AR, and HT
aims to reduce activation of the AR by blocking androgen
production and/or binding. This is achieved by reducing the
amount of circulating androgens using LHRH analogues/
agonists and through the use of competitive antagonists,
called anti-androgens, which prevent androgens from
binding to the AR [75]. Despite initial response, the
majority of PCa patients develop resistance to this treatment
and the disease progresses to the therapy resistant stage,
termed Castrate Resistant Prostate Cancer (CRPC). RSKs
have been shown to play a role in some of the mechanisms
that have been proposed to explain CRPC [76].
RSK1 has been shown to regulate the AR transcriptional
program via YB1 in LNCaPs in response to androgen
depletion [77]. Indeed, androgen depletion of LNCaP cells
caused an increase in AR expression and enhanced phos-
phorylation of both RSK1 and YB1. Similar results were
also observed when cells were treated with the anti-
androgen drug enzalutamide [77]. Antiandrogens and
Androgen-Deprivation Therapy (ADT) are common treat-
ment options for PCa that aim to attenuate AR signaling by
either reducing levels of circulating testosterone or pre-
venting AR activation. It has been shown that RSK1
reduces the efficiency of ADT by upregulation of AR
expression, promoting receptor activation even at low
androgens levels. This drives PCa progression to CRPC and
is a common mechanism by which therapy resistance
develops in PCa [78]. In response to antiandrogen treatment
RSK1 phosphorylates YB1 at S102, which promotes its
nuclear localisation and binding to its cognate Y-box within
the response element [79]. Dolfini and Mantovani [80] have
challenged the notion that YB1 is a transcription factor able
to directly bind DNA [81]. Extensive analysis of Chip-seq
coupled with ribonuclease treatment suggests that YB1 may
be promoting gene expression by posttranscriptional
mechanisms through RNA binding. Independently from the
exact mechanism of action of YB1, in LNCaPs and C4-2B
cells, RSK1-YB1 regulation of the AR transcriptional pro-
gram was shown to promote cell survival and reduce anti-
androgen efficacy by enhancing expression of cyclin D1,
E2F-1 and phosphorylation of Retinoblastoma protein (Rb)
[77] (Fig. 4D). To overcome RSK-induced therapy resis-
tance, Law et al. [82] used a cell permeable peptide, which
competes with YB1 for RSK2, resulting in a reduction of
YB1 S102 phosphorylation. Treatment with this peptide
reduced YB1 translocation to the nucleus and inhibited the
growth of PCa and BCa cell lines [82]. Interestingly, there
are additional known and predicted phosphorylation sites on
YB1, some of which have not yet been linked to a kinase
in vivo [83]. Thus, it is possible that the RSKs could fine
tune YB1 activity via several phosphorylation events which
could also influence PCa progression and chemoresistance.
RSK1 was also shown to promote resistance to
LY294002 (LY), a PI3K inhibitor [84]. Treatment of
LNCaP cells with LY induced cell death, but co-treatment
with EGF blocked LY-induced cell death in these cells.
Further investigation showed that, downstream of EGF
signaling, MEK/ERK/RSK1 inactivated Bcl2-associated
Agonist of cell Death (BAD) via S75 phosphorylation,
causing inhibition of apoptosis [84]. Zoubeidi et al. [85]
showed that in PCa, Insulin-like Growth Factor I (IGF-I)
signaling triggered activation of both the MAPK and PI3K/
Akt pathways, promoting cell survival and a reduction in
the efficacy of the pro-apoptotic drug cycloheximide. IGF-I
activation of MAPK resulted in activation of RSKs, which
in turns phosphoactivates Hsp27. Importantly, Hsp27
expression and phosphorylation levels were shown to cor-
relate with PCa disease progression and were elevated in
response to androgen ablation in both patient samples and
PCa cell lines [85]. Phosphorylated Hsp27 can increase cell
survival by potentiating the IGF-I induced activation of Akt,
ERK and RSK, which leads to the phosphorylation of BAD
on S75 and S99, stabilising BAD-14-3-3 complex and
therefore reducing apoptosis [85] (Fig. 4D). Compared to
previous studies [84] the authors identified an additional
phosphorylation on S99. This is possibly the result of a
convergence of the MAPK and PI3K pathways, which has
been previously characterized in BCa and might also exist
The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance
in PCa. Specifically, studies in BCa demonstrated that IGF
can stimulate transactivation of the EGF receptor (EGFR) in
the absence of EGF, leading to activation of the MAPK
pathway and phosphorylation of BAD [86]. ZD1839, an
EGFR inhibitor, was shown to potently induce apoptosis by
blocking the MAPK activation, resulting in BAD depho-
sphorylation on S75. On the contrary, phosphorylation of
BAD on S99 was not altered by ZD1839, confirming that
this phosphorylation was independent of the EGFR-MAPK
pathway and was indirectly targeted by PI3K. However,
S99 was not sufficient to maintain survival when cells were
treated with ZD1839. Similar cell survival mechanisms
were also identified in melanoma cells, which also develop
chemoresistance via RSK inactivation of BAD [87].
RSK inhibitors and future directions
The growing body of evidence demonstrating the role of
RSKs in cancer has prompted drug development studies
aimed at identifying RSKs-specific inhibitors [45, 88]. The
first three small molecules proposed as RSK inhibitors were
FMK, SL0101 and BI-D1870 [89]. The inhibition
mechanisms differ among these compounds: FMK is an
irreversible RSK1/2/4-CTKD inhibitor, while BI-D1870
and SL0101 are RSKs-NTKD ATP-competitors [89]. FMK
has two major limitations: it does not prevent CTKD-
independent activations and it does not inhibit RSK3
[90, 91]. On the contrary, SL0101 and BI-D1870 are pan-
RSK inhibitors but lack selectivity. In fact, SL0101 has an
overall high EC50 in cells, indicating poor cellular activity
[30], while high concentrations of BI-D1870 has been
shown to inhibit several other kinases (i.e., PLK1, Aurora
B, MELK, PIM3, MST2, and GSK3b), suggesting that
many of the reported cellular effects of BI-D1870 are likely
the result of non-specific interactions [92, 93]. Importantly,
a recent study comparing BI-D1870 and SL0101 activity
showed that, in an RSK-independent mechanism, BI-D1870
increases S6K1 phosphorylation, while SL0101 directly
inhibits mTORC1. This highlights the importance of using
different approaches to confirm the results obtained in stu-
dies using SL0101 or BI-D1870 to inhibit RSKs [92].
Drug design studies aimed to increase the selectivity and
potency of BI-D1870, generated two novel compounds,
LJI308 and LJH685 [94]. While these two molecules have
lower EC50 values than the previous RSK NTKD ATP
competitors [94], their poor pharmacokinetic profiles made
them unsuitable for in vivo use [45, 88]. The first, to our
knowledge, clinical trial testing an RSK inhibitor in cancer
patients was announced in November 2019: Pheonix
Molecular Designs initiated a Phase 1/1b clinical trial to
evaluate the safety and tolerability of PMD-026 in patients
with metastatic Bca and Triple Negative Breast Cancer
(Clinical Trials ID: NCT04115306).
Ludwik and Lannigan [88] suggested that the develop-
ment of inhibitors targeting the upstream MAPK pathway
has meant that drug development for the RSKs has been
limited. The MEK1/2 inhibitors trametinib, binimetinib and
cobimetinib have been approved for treatment of melanoma
and BRAF-mutant non-small cell lung cancer, and several
more MEK1/2 drugs are currently in clinical trials [95, 96].
However, acquired resistance to these treatments is common
and several studies have explored the option to target more
nodes of the signaling cascade to resensitise tumor cells to
treatments [95]. For example, it has been shown in vitro that
dual inhibition of MEK and ERK can be used to overcome
resistance to MEK inhibitors in several different cancer cell
lines [97]. Using an RSK inhibitor as part of a therapeutic
cocktail would present several advantages. In fact, RSKs
regulate fewer processes than ERK, for example in kidney
epithelial cells ERK regulates the expression of 1089 genes,
while RSK regulates only 228 genes [69]. Furthermore,
studies on BCa have shown that inhibition of RSK1/2 does
not affect the proliferation of normal breast epithelial cells,
which is an advantage compared to some of the MEK
inhibitors [98]. Similarly, RSKs inhibition has been used to
resensitise GBM cells to the standard chemotherapy drug
temozolomide [99]. Specifically, RSK2 plays a key role in
GBM progression and treatment of a GBM-derived cell line
with a combination of temozolomide and BI-D1870 showed
an additive antitumor effect. Importantly, the drugs had
little effect on cell proliferation when used separately at the
same low concentration, reducing the risk of toxicity in
normal tissues [99]. Despite clear indications that RSKs are
viable targets for cancer treatment/co-treatment, the use of
RSKs inhibitors in the clinic is still limited. Indeed,
increasing evidence suggests that different RSK isoforms
perform tissue-specific and sometimes opposing functions
in cancer. While no data is available for RSK3/4 in PCa,
studies in lung and BCa have shown that RSK1 and RSK4
have diametrically opposing roles in diseases progression
[27]. This suggests that the use of pan-RSK inhibitors may
yield distinct toxicity effects and may not be optimal for
anti-cancer treatments [100]. Consequently, selective RSK-
isoform specific inhibition represents a more promising way
to target RSKs in cancer. Future studies on RSK-isoform
specific inhibitors used as monotherapies or as part of
combination therapies, for the treatment of PCa, are there-
fore warranted.
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